Tag:
CEP-37247
Latest Headlines
Latest Headlines
Cephalon snags $30M option on BioAssets
Cephalon has agreed to pay $30 million for an option to buy Wellesley, MA-based BioAssets Development Corp., which is pursuing new TNF inhibitors for sciatic pain in patients with intervertebral disk
